Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial.

Registry ID

EUCTR2008-001340-39

Source registry

EUCTR

Status

Ongoing

Phase

PHASE3

Sponsor

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA

Start date

2008-06-30

Last update

2026-08-16

Conditions

• Pulmonary Sarcoidosis

Summary

The aim of the study is to determine the safety for a combination therapy with hydroxychloroquine plus low dose GCs compared to that for high dose GCs at 3 and 9 months in patients with pulmonary sarcoidosis.

Locations

• , , Italy

Related clinical trials

• An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
• Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
• Role of Genetic Factors in the Development of Lung Disease
• A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
• Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis
• Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis

View on source registry